Tildrakizumab-asmn
Class: Skin and Mucous Membrane Agents, Miscellaneous
Molecular Formula: C6426H9918N1698O2000S46
CAS Number: 1326244-10-3
Brands: Ilumya
Introduction
Inhibitor of interleukin-23 (IL-23), a proinflammatory cytokine; a recombinant humanized IgG1 kappa monoclonal antibody that binds specifically to the p19 subunit of IL-23.
Uses for Tildrakizumab-asmn
Plaque Psoriasis
Management of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy.
Tildrakizumab-asmn Dosage and Administration
General
Pretreatment Screening
Evaluate patients for tuberculosis prior to initiation of tildrakizumab therapy.
Administration
Sub-Q Administration
Manufacturer states tildrakizumab-asmn should only be administered by a clinician.
Available as single-use, prefilled syringes.
If previously refrigerated, allow prefilled syringe to sit at room temperature inside the closed carton for 30 minutes prior to injection. Do not remove the needle cap while the drug is warming to room temperature.
Do not shake the injection.
No need to remove air bubbles if present in syringe.
Administer by sub-Q injection into an accessible area with clear skin (e.g., upper arm, anterior thigh, lower abdomen); do not make abdominal injections within 2 inches of the navel. Do not make injections into areas where the skin is tender, bruised, red, or indurated. Do not inject into psoriatic lesions, scars, stretch marks, or blood vessels.
Dosage
Adults
Plaque Psoriasis
Sub-Q
100 mg at 0 and 4 weeks, then every 12 weeks.
If a dose is missed, administer the missed dose as soon as possible and resume dosing at the regularly scheduled interval.
Special Populations
Hepatic Impairment
Manufacturer makes no specific dosage recommendations.
Renal Impairment
Manufacturer makes no specific dosage recommendations.
Geriatric Patients
Manufacturer makes no specific dosage recommendations.
Cautions for Tildrakizumab-asmn
Contraindications
Serious hypersensitivity reaction to tildrakizumab or any ingredient in the formulation.
Warnings/Precautions
Hypersensitivity Reactions
Hypersensitivity reactions (e.g., angioedema, urticaria) reported. If a serious hypersensitivity reaction occurs, discontinue tildrakizumab immedi...